We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom to Launch 15-Day G7 CGM System in Canada This November
Read MoreHide Full Article
Key Takeaways
DexCom plans to launch its G7 15 Day CGM in Canada in November, offering up to 15.5 days of sensor wear.
The new system offers 8.0% MARD, with waterproof sensors, Apple Watch connectivity and customizable alerts.
Public and private reimbursement coverage could expand access and support DexCom's international growth.
DexCom (DXCM - Free Report) recently announced the upcoming Canadian launch of its Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people aged 18 years and older living with diabetes. Starting in November, the next-generation system will offer up to 15.5 days of sensor wear, combining longer usage with an overall mean absolute relative difference (MARD) of 8.0% for improved glucose monitoring with fewer sensor changes.
Per management, Dexcom G7 15 Day is designed to make glucose monitoring simpler and more seamless for people living with diabetes. The new system combines extended sensor life with accuracy and performance. The product's launch in Canada will also be supported by substantial public and private reimbursement coverage, expanding access to the technology.
DXCM Stock Trend Following the News
DXCM stock has gained 7.8% since the announcement on Wednesday. Year to date, the stock has gained 27.7%, outperforming the industry’s 0.4% growth and the S&P 500’s 9.3% rise.
The Canadian launch could support DexCom's international growth by expanding the reach of its latest CGM technology in a market where reimbursement coverage is expected to facilitate adoption. Longer sensor wear may also improve the product's appeal among patients seeking more convenient diabetes management solutions. Wider access to the G7 platform could help strengthen DexCom's competitive position and support continued demand for its glucose biosensing products.
DXCM currently has a market capitalization of $30.69 billion.
Image Source: Zacks Investment Research
More on the News
The Dexcom G7 15 Day is designed to provide real-time glucose readings for up to 15.5 days, reducing the frequency of sensor replacements and interruptions to daily routines. Its overall MARD of 8.0% reflects its accuracy performance. The system builds on DexCom's existing CGM technology, which has demonstrated clinical benefits, including lower A1C levels and increased time in range.
The device retains several features of the existing Dexcom G7 platform, including waterproof sensors, direct connectivity to Apple Watch, a 12-hour grace period for sensor replacement and integration with the Dexcom Clarity app. Users can review glucose patterns and trends, share readings remotely with caregivers and customize alerts to support more personalized diabetes management.
Eligible Canadians with Type 1 and Type 2 diabetes will have access to public reimbursement beginning in November. Private health plans that currently cover CGMs are also expected to add coverage for the new system, potentially broadening its addressable patient base.
DexCom is also working with its automated insulin delivery partners to extend the launch to their customers as integration efforts are finalized.
Industry Prospects Favoring the Market
According to Grand View Research, the global CGM devices market is estimated to be valued at $15.5 billion in 2026 and is projected to witness a CAGR of 15.1% through 2033.
Factors such as the rising prevalence of diabetes, increasing demand for real-time glucose monitoring, growing adoption of advanced wearable CGM technologies, expanding reimbursement coverage and technological improvements in sensor accuracy, connectivity and wear duration are expected to drive market growth.
Other News
DexCom recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the Dexcom G7 CGM system in adults with Type 2 diabetes not using insulin.
The 26-week study involved 440 participants across 22 U.S. primary care sites. Participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%, a 0.9% greater reduction than routine care. The findings support earlier CGM adoption in Type 2 diabetes care.
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Bigstock
DexCom to Launch 15-Day G7 CGM System in Canada This November
Key Takeaways
DexCom (DXCM - Free Report) recently announced the upcoming Canadian launch of its Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people aged 18 years and older living with diabetes. Starting in November, the next-generation system will offer up to 15.5 days of sensor wear, combining longer usage with an overall mean absolute relative difference (MARD) of 8.0% for improved glucose monitoring with fewer sensor changes.
Per management, Dexcom G7 15 Day is designed to make glucose monitoring simpler and more seamless for people living with diabetes. The new system combines extended sensor life with accuracy and performance. The product's launch in Canada will also be supported by substantial public and private reimbursement coverage, expanding access to the technology.
DXCM Stock Trend Following the News
DXCM stock has gained 7.8% since the announcement on Wednesday. Year to date, the stock has gained 27.7%, outperforming the industry’s 0.4% growth and the S&P 500’s 9.3% rise.
The Canadian launch could support DexCom's international growth by expanding the reach of its latest CGM technology in a market where reimbursement coverage is expected to facilitate adoption. Longer sensor wear may also improve the product's appeal among patients seeking more convenient diabetes management solutions. Wider access to the G7 platform could help strengthen DexCom's competitive position and support continued demand for its glucose biosensing products.
DXCM currently has a market capitalization of $30.69 billion.
Image Source: Zacks Investment Research
More on the News
The Dexcom G7 15 Day is designed to provide real-time glucose readings for up to 15.5 days, reducing the frequency of sensor replacements and interruptions to daily routines. Its overall MARD of 8.0% reflects its accuracy performance. The system builds on DexCom's existing CGM technology, which has demonstrated clinical benefits, including lower A1C levels and increased time in range.
The device retains several features of the existing Dexcom G7 platform, including waterproof sensors, direct connectivity to Apple Watch, a 12-hour grace period for sensor replacement and integration with the Dexcom Clarity app. Users can review glucose patterns and trends, share readings remotely with caregivers and customize alerts to support more personalized diabetes management.
Eligible Canadians with Type 1 and Type 2 diabetes will have access to public reimbursement beginning in November. Private health plans that currently cover CGMs are also expected to add coverage for the new system, potentially broadening its addressable patient base.
DexCom is also working with its automated insulin delivery partners to extend the launch to their customers as integration efforts are finalized.
Industry Prospects Favoring the Market
According to Grand View Research, the global CGM devices market is estimated to be valued at $15.5 billion in 2026 and is projected to witness a CAGR of 15.1% through 2033.
Factors such as the rising prevalence of diabetes, increasing demand for real-time glucose monitoring, growing adoption of advanced wearable CGM technologies, expanding reimbursement coverage and technological improvements in sensor accuracy, connectivity and wear duration are expected to drive market growth.
Other News
DexCom recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the Dexcom G7 CGM system in adults with Type 2 diabetes not using insulin.
The 26-week study involved 440 participants across 22 U.S. primary care sites. Participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%, a 0.9% greater reduction than routine care. The findings support earlier CGM adoption in Type 2 diabetes care.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
DXCM’s Zacks Rank & Key Picks
Currently, DexCom carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.